Pérez-Cruz E, Asbun-Bojalil J, Reyes-Marín A, Rodríguez-Wong U, Ruiz-Pérez NJ, Sánchez-Navarrete J, Montes-Vera MR, Cruz-Rico J

Language: Spanish
References: 28
Page: 20-27
PDF size: 207.50 Kb.

ABSTRACT

Increased consumption of N-3 polyunsaturated fatty acids (PUFAs) in form of fish or fish oil supplements proved beneficial effect in epidemiological and experimental studies on biological processes involved in cardiovascular diseases. N-3 PUFAs have immunomodulating effect and anti-inflammatory activity in arthritis, Crohn’s disease, ulcerative colitis, systemic lupus erythematosus and other autoimmune disease. Weight loss is common in cancer patients; additional cachexia in advanced stages associated a lower quality of life and short survival. N-3 PUFAs modulate effectors pathways in oncology processes, reduce weight loss, promoting weight gain and increase the survival in cachexia associated with cancer. However, N-3 PUFAs effect depend bioactive structure by typo of food, bio-availability, dose and local tissue concentration. We review the factors that promote weight lost and malnutrition in cancer patients and effects that N-3 PUFAs have on cancer-associated cachexia.

REFERENCES

1. Organización Mundial de la Salud. Cáncer. Nota descriptiva No. 297, julio 2008. Disponible en: http//www.who.int/ mediacentre/factsheets/fs297/es/index.html [Actualizada: 2011].

2. Instituto Nacional de Estadística y Geografía (INEGI). Disponible en: http//www.inegi.org.mx/inegi/contenidos/español/ prensa/default.asp?c=269&e [Actualizada: 2011].

3. Greenlee RT, Murray T, Bolden S, Wingo P. Cancer statistcs. CA Cancer J Clin 2000; 50: 7-33.

4. Gunerhan Y, Neset K, Sahin U, Uzun M, Demiralp E. Effect of preoperative inmunonutrition and other nutrition models on cellular immune parameters. WJG 2009; 15(4): 467-72.

5. Staber P, Langner S, Jurgen D, Neumeister P. Antifungal management in cancer patients. Wien Med Wochenschr 2007; 127(20): 503-10.

6. Arranz M, Aller R, Cuellar L, et al. Immunoenhanced enteral nutrition, effect on inflammatory markers in head and neck cancer patients. Eur J Clin Nut 2005; 59: 145-7.

7. Karel W, Hulsewe M, Bemadette A, et al. Nutritional depletion and dietary manipulation: effects on the immune response. World J Surg 1999; 23(6): 536-44.

8. Jatoi A, Kumar S, Sloan J, Bguyen P. On appetite and its loss. J Clin Oncol 2000; 18(15): 2930-2.

9. Yoichi S, Yuriko O, Shiho K, et al. Effects of long-term continuous use of immune-enhancing enteral formula on nutritional and immunologic status in non-surgical patients. Nutrition 2006; 22: 713-21.

10. Correira M, Cravo M, Marques-Vidal P, et al. Serum concentrations of TNF-alpha as a surrogate marker for malnutrition and worse quality of life in patients with gastric cancer. Clin Nutr 2007; 26(6): 728-35.

11. Scott HR, McMillan DC, Brown DJ, et al. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable nonsmall cell lung cancer. Lung Cancer 2003; 40(3): 295-9.

12. Gómez Candela C, Villarino Sanz M, Horrisberger A, et al. Efficacy Evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients. Nutr Hosp 2011; 26(6): 1385-93.

13. Takatsuka H, Takemoto Y, Iwata N, et al. Oral eicosapentaenoic acid for complications of bone marrow transplantation. Bone Marrow Transplant 2001; 28: 769-74.

14. Burdge G. Alpha linolenic acid metabolism in men and women: nutritional and biological implications. Curr Opin Clin Nutr Metab Care 2004; 7: 137-44.

15. Eaton SB, Konner M. Paleolithic nutrition. A consideration of its nature and current implications. N Eng J Med 1985; 312: 283-9.

16. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutrition 2002; 21(6): 495-505.

17. Bosaeus I. Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer 2008; 16: 447-51.

18. Chapkin RS, Kim W, Lupton JR, et al. Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot Essent Fatty Acids 2009; 81: 187-91.

19. Kim W, McMurray DN, Chapkin RS. N-3 polyunsaturated fatty acids-physiological relevance of dose. Prostaglandins Leukot Essent Fatty Acids 2010; 82(4-6): 155-8.

20. US Department of Healt and Human Services AfHRaQ. Effects of omega-3 fatty acids on cardiovascular disease. Evid Rep Technol Assess 2004; 1-8.

21. Morlion BJ, Torwesten E, Lessire H, et al. The effect of parenteral fish oil on leukocyte membrane fatty acid composition and leukotriene-synthesizing capacity in patients with postoperative trauma. Metabolism 1996; 45: 1208-13.

22. Heller AR, Rossler S, Gottschlich B, et al. Omega 3-fatty acids improve liver and pancreas function in postoperative cancer patients. Int J Cancer 2004; 111: 611-6.

23. Wachtler P, Konin W, Senkal M, et al. Influence of a total parenteral nutrition enriched with omega-3 fatty acids on leukotriene synthesis of peripheral leukocytes and systemic cytokine levels in patients with major surgery. J Trauma 1997; 42: 191-8.

24. Weiss G, Meyer F, Matthies B, et al. Inmunomodulation by perioperative administration of n-3 fatty acids. Br J Nutr 2002; 87(S1): S89-S94.

25. Administration USFaD. Safety reporting requirements for human drug and biological products. 2003; 21 CFR Part 310,312,314,320,00,606.

26. Dewey A, Baughan C, Dean TP, et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database of Systematic Reviews 2007. Issue I Art No. CD004597. DOI:10.1002/ 14651858.CD004597 pub2.

27. Colomer R, Moreno-Nogueira JM, García-Luna PP, et al. N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 2007; 97(5): 823-31.

28. Allen August D, Huhmann MB; American Society for Parenteral and Enteral Nutrition (ASPEN) Board of Directors. Clinical Guidelines: Nutrition Support Therapy during Adult Anticancer Treatment and in Hematopoietic Cell Transplantation. JPEN 2009; 33: 472.